Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709289 | 0.86 | SMN1; SMN2 (0.50) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| Bromide SCHEMBL31141380 | 0.85 | SMN1; SMN2 (0.49) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| SCHEMBL20572266 | 0.77 | SMN1; SMN2 (0.51) | — | |
| SCHEMBL6663737 | 0.76 | SLC6A3 (0.46) | SIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL20569188 | 0.75 | TAAR1 (0.42) | SIGMAR1 | |
| SCHEMBL20569164 | 0.75 | SLC6A3 (0.54) | SIGMAR1DAO | |
| SCHEMBL24709610 | 0.73 | ALDH1A1 (0.46) | SIGMAR1 | |
| SCHEMBL11730441 | 0.72 | MAPT (0.65) | SIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL2291008 | 0.72 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP2D6TMEM97 | |
| Bromide SCHEMBL31141392 | 0.71 | ALDH1A1 (0.45) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179361-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | TORREY PINES INST FOR MOLECULAR STUDIES (US) | 2020-06-11 | — | — | US | disclosed |
| WO-2018217631-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179361-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | CHRNA4, CHRNA5, CHRNB4 | SIGMAR1 236/4885CYP1A2 2302/4885CYP2D6 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.